Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation

Journal of Molecular and Cellular Cardiology

Volumn 37, Issue 3, 2004, Pages 699-704

  Marín, Francisco ^a   Corral, Javier ^b   Roldán, Vanessa ^c   González Conejero, Rocío ^b   Del Rey, María Luz ^b   Sogorb, Francisco ^a   Lip, Gregory Y H ^d   Vicente, Vicente ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c Hospital de San Vicente   (Spain)

^d CITY HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Inflammation; Polymorphism; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; INTERLEUKIN 6; LEUCINE; PADGEM PROTEIN; THROMBOPLASTIN; VALINE;

AGED; ALLELE; ARTICLE; ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GEOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINUS RHYTHM; THROMBOSIS;

AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; ATRIAL FIBRILLATION; FACTOR XIII; FEMALE; FIBRINOGEN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; P-SELECTIN; POLYMORPHISM, GENETIC; THROMBOPLASTIN;

EID: 4444378715     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.06.001     Document Type: Article

References (39)

1. Lip G.Y.H. Does atrial fibrillation confer a hypercoagulable state? Lancet. 346:1994;1313-1314
2. Lip G.Y.H., Lip P.L., Zafiris J., Watson R.D., Bareford D., Lowe G.D.O., et al. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation. 94:1996;425-431
3. Heppell R.M., Berkin K.E., McLenachan J.M., Davies J.A. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 77:1997;407-411
4. McEver R.P., Moore K.L., Cummings R.D. Leukocyte trafficking mediated by selectins-carbohydrate interactions. J Biol Chem. 270:1995;11025-11028
5. Roldán V., Marín F., Blann A.D., García A., Marco P., Sogorb F., et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J. 24:2003;1373-1380
6. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Cardnes C.A., et al. C-reactive protein elevation in patients with atrial fibrillation. Circulation. 104:2001;2886-2891
7. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 108:2003;3006-3010
8. Kamath S., Blann A.D., Chin B.S.P., Lip G.Y.H. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 40:2002;489-490
9. Chung N.A.Y., Belgore F., Li-Saw-Hee F.L., Conway D., Blann A.D., Lip G.Y.H. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 33:2002;2187-2191
10. Edgington T.S., Mackman N., Brand K., Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 66:1991;67-79
11. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:1993;513-520
12. Muszbek L., Yee V.C., Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 94:1999;271-305
13. Mikkola H., Syrjala M., Rasi V., Vahtera E., Hamalainen E., Peltonen L., et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 84:1994;517-525
14. Kohler H.P., Stickland M.H., Ossei-Gernig N., Carter A., Mikkola H., Grant P.J. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 79:1998;8-13
15. Aleksic N., Ahn C., Wang Y.W., Juneja H., Folsom A.R., Boerwinkle R., et al. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 22:2002;348-352
16. Corral J., González-Conejero R., Iniesta J.A., Rivera J., Martínez C., Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica. 85:2000;293-297
17. Ariëns R.A.S., Lai T.S., Weisel J.W., Greenberg C.S., Grant P.J. Role of factor XIII in fibrin clot formation and effects of genetic polymorphism. Blood. 100:2002;743-754
18. Kangsadalampai S., Board P.G. The Val34Leu polymorphism in the A subunit coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 92:1998;2766-2770
19. Ariëns R.A.S., Philippou H., Nagaswami C., Weisel J.W., Lane D.A., Grant P.J. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 96:2000;988-995
20. Balogh I., Szöke G., Kárpáti L., Wartiovaarar U., Katona E., Komáromi I., et al. Val34Leu polymorphism of plasma FXIII: biochemistry and epidemiology in familial thrombophilia. Blood. 96:2000;2479-2486
21. Schroeder V., Chatterjee T., Kohler H.P. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography. Thromb Res. 104:2001;467-474
22. Roldán V., Corral J., Marín F., Rivera J., Vicente V. Effects of factor XIII Val34Leu polymorphism on thrombolytic therapy in premature myocardial infarction. Thromb Haemost. 88:2002;354-355
23. Kim S.Y., Jeitner T.M., Steinert P.M. Transglutaminases in disease. Neurochem Int. 40:2002;85-103
24. Libby P., Simon D.I. Inflammation and thrombosis. The clot thickens. Circulation. 103:2001;1718-1720
25. Roldán V., Corral J., Marín F., Rivera J., González-Conejero R., Sogorb F., et al. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol. 91:2003;1242-1245
26. Canavy I., Henry M., Morange P.E., Tiret L., Poirier O., Ebagosti A., et al. Genetic polymorphism and coronary artery disease in the south of France. Thromb Haemost. 83:2000;212-216
27. Alhenc-Gelas M., Reny J.L., Aubry M.L., Aiach M., Emmerich J. The FXIII Val 34 Leu mutation and the risk of venous thrombosis. Thromb Haemost. 84:2000;1117-1118
28. Conway D.S.G., Pearce L.A., Chin B.S.P., Hart R.G., Lip G.Y.H. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 107:2003;3141-3145
29. Vene N., Mavri A., Kosmelj K., Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 90:2003;1163-1172
30. Lip G.Y.H. The prothrombotic state in atrial fibrillation: the atrium, the endothelium,... and tissue factor? Thromb Res. 111:2003;133-135
31. Feinberg W.M., Pearce L.A., Hart R.G., Cushman M., Cornell E.S., Lip G.Y.H., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke. 30:1999;2547-2553
32. Pengo V., Filippi B., Biasiolo A., Pegoraro C., Naventa F., Iliceto S. Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. Am J Cardiol. 90:2002;545-546
33. Poli D., Antonucci E., Cecchi E., Betti I., Valdrè L., Mugnaini C., et al. Thrombophilic mutations in high-risk atrial fibrillation patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. Thromb Haemost. 90:2003;1158-1162
34. Carter A.M., Catto A.J., Grant P.J. Association of the α-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation. 99:1999;2423-2426
35. Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 131:1999;688-695
36. Nakamura Y., Nakamura K., Fukushima-Kusano D., Ohta K., Matsubara H., Hamuro T., et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 101:2003;137-142
37. Chen R., Doolittle R.T. Isolation, characterization and location of a donor-acceptor unit from cross-linked fibrin. Proc Natl Acad Sci USA. 66:1970;474-479
38. Muszbek L., Adany R., Mikkola H. Novel aspects of blood coagulation factor XIII, I: structure, distribution, activation, and function. Crit Rev Clin Lab Sci. 33:1996;357-421
39. Conway D., Buggins P., Hughes E.A., Lip G.Y.H. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 43:2004;2075-2082